• ქართული
  • English
  • Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

    LONDON (Reuters) – For Christophe Weber, the boss of Japan’s Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

    Market Quotes by TradingView